Alpha Teknova, Inc. (TKNO) Bundle
An Overview of Alpha Teknova, Inc. (TKNO)
General Summary of Alpha Teknova, Inc. (TKNO)
Alpha Teknova, Inc. (TKNO) is a biotechnology company based in Hollister, California, specializing in the development and production of critical reagents and consumables for the life sciences industry. The company was founded in 1998 and has evolved to meet the growing demands of research and clinical laboratories worldwide. As of 2024, Teknova's product offerings include Lab Essentials, which encompasses a range of laboratory consumables, and Clinical Solutions, which provides specialized products for clinical applications.
As of September 30, 2024, Alpha Teknova reported total sales of approximately $28.5 million, with $27.2 million derived from U.S. sales, accounting for 95.3% of total revenue, and $1.3 million from international sales, representing 4.7%.
Company's Financial Performance in the Latest Financial Reports
For the nine months ended September 30, 2024, Alpha Teknova generated total revenue of $28.48 million, a slight decrease of 1.2% compared to $28.82 million in the same period of the previous year. The revenue breakdown is as follows:
| Product Category | 2024 Revenue (in $ thousands) | 2023 Revenue (in $ thousands) | $ Change | % Change |
|---|---|---|---|---|
| Lab Essentials | 22,065 | 22,112 | (47) | (0.2) |
| Clinical Solutions | 5,247 | 5,859 | (612) | (10.4) |
| Other | 1,168 | 846 | 322 | 38.1 |
Gross profit for the nine months ended September 30, 2024, was $5.1 million, a decline of 43.1% from $9.0 million in 2023. The gross profit percentage was 17.9%, down from 31.1% in the prior year, primarily due to $2.8 million in non-recurring charges related to inventory write-downs.
Operating expenses for the same period totaled $25.6 million, a reduction of 23.9% from $33.7 million in the prior year. This decrease was attributed to lower research and development costs, sales and marketing expenditures, and general and administrative expenses.
Net loss for the nine months ended September 30, 2024, was $21.0 million compared to a loss of $26.1 million for the same period in 2023, reflecting a 19.5% improvement.
Introduction to Company as a Leader in the Industry
Alpha Teknova, Inc. is recognized as a key player in the biotechnology sector, particularly in the supply of essential reagents and consumables for laboratories. The company has positioned itself strategically to cater to the increasing demand for high-quality lab products amid advancements in life sciences research and clinical diagnostics. With a commitment to innovation and quality, Teknova continues to expand its customer base and product offerings, thereby reinforcing its status as a leader in the industry.
As of 2024, Alpha Teknova's growth trajectory and financial resilience are indicative of its potential for continued success in the rapidly evolving biotechnology landscape.
Mission Statement of Alpha Teknova, Inc. (TKNO)
Mission Statement Overview
The mission statement of Alpha Teknova, Inc. (TKNO) serves as a guiding framework for the company, articulating its core purpose and strategic direction. The mission emphasizes the commitment to delivering high-quality products and services that meet the evolving needs of customers in the life sciences sector. This focus is crucial for aligning company objectives with market demands and establishing a strong competitive position.
Core Component 1: Quality Products
Alpha Teknova is dedicated to providing high-quality products that adhere to rigorous standards. The company is ISO 13485:2016 certified, which allows it to manufacture products for diagnostic and therapeutic applications. This certification underscores Teknova's commitment to quality assurance and regulatory compliance, which are essential for gaining customer trust in the life sciences industry.
As of September 30, 2024, Teknova reported a gross profit margin of 17.9% for the nine months ended, a significant decrease from 31.1% in the previous year, primarily due to non-recurring charges related to inventory management.
Core Component 2: Customer-Centric Approach
Alpha Teknova prioritizes a customer-centric approach, aiming to support customers throughout the product development lifecycle. The company's mission reflects its focus on understanding client needs and delivering tailored solutions that enhance operational efficiency. For instance, during the three months ended September 30, 2024, Clinical Solutions revenue surged by 229.0%, reaching $2.0 million, indicating a strong demand for Teknova's offerings.
Furthermore, total revenue for the same period was $9.6 million, illustrating a robust growth trajectory compared to $8.2 million in the previous year.
Core Component 3: Innovation and Growth
Innovation is a central theme in Alpha Teknova's mission statement, driving the company to invest in research and development. In the nine months ended September 30, 2024, R&D expenses amounted to $2.2 million, a reduction of 49.1% compared to $4.3 million in the previous period. This reduction reflects strategic adjustments aimed at improving operational efficiency while maintaining a focus on innovative product development.
Looking ahead, Teknova aims to expand its manufacturing capacity and enhance its infrastructure to support future growth. The investment in a new state-of-the-art manufacturing facility is a testament to this commitment, positioning the company to meet increasing market demands effectively.
| Financial Metric | 2024 (YTD) | 2023 (YTD) | Change ($) | Change (%) |
|---|---|---|---|---|
| Total Revenue | $28.5 million | $28.8 million | $(0.3) million | (1.2%) |
| Gross Profit | $5.1 million | $9.0 million | $(3.9) million | (43.1%) |
| Operating Expenses | $25.6 million | $33.7 million | $(8.0) million | (23.9%) |
| Net Loss | $(21.0) million | $(26.1) million | $5.1 million | (19.5%) |
Vision Statement of Alpha Teknova, Inc. (TKNO)
Vision Statement Overview
The vision statement of Alpha Teknova, Inc. (TKNO) for 2024 emphasizes the company's commitment to being a leader in the life sciences sector by providing innovative, high-quality products that support advancements in diagnostics and therapeutics. The focus is on enhancing customer experiences and meeting the evolving needs of the healthcare industry.
Commitment to Innovation
Alpha Teknova's vision highlights a strong commitment to innovation. The company aims to leverage its proprietary manufacturing processes to deliver high-quality, custom products rapidly. As of September 30, 2024, Teknova reported revenue of $9.6 million for the quarter, an increase of 17.2% compared to $8.2 million for the same period in 2023.
Quality Assurance and Compliance
Quality assurance is a critical component of Teknova's vision. The company is ISO 13485:2016 certified, which enables the manufacturing of products for diagnostic and therapeutic applications. This certification supports Teknova's goal of providing solutions that meet stringent quality requirements as customers scale from research to commercialization.
Customer-Centric Approach
Alpha Teknova's vision underscores a customer-centric approach, aiming to enhance customer satisfaction through tailored solutions. The company reported that revenue from Clinical Solutions increased by 229% year-over-year to $2.0 million in the third quarter of 2024, driven by a growing customer base. This increase reflects Teknova's ability to adapt to customer needs effectively.
Sustainable Growth and Operational Efficiency
Alpha Teknova aims for sustainable growth while improving operational efficiency. The company reduced its operating expenses by 26.5% year-over-year to $7.5 million for the third quarter of 2024. This reduction was primarily due to decreased spending in research and development, sales and marketing, and general and administrative areas, indicating a strategic focus on cost management.
Global Reach and Market Expansion
The vision also includes plans for global reach and market expansion. For the nine months ended September 30, 2024, international sales accounted for 4.7% of total revenue, showing a modest increase from 4.1% in the same period of 2023. This growth reflects Teknova's efforts to penetrate international markets while maintaining a strong domestic presence, with U.S. sales representing 95.3% of total revenue during the same period.
| Financial Metrics | Q3 2024 | Q3 2023 | Change (%) |
|---|---|---|---|
| Total Revenue | $9.6 million | $8.2 million | 17.2% |
| Gross Profit | $0.09 million | $1.47 million | (93.9%) |
| Operating Expenses | $7.5 million | $10.2 million | (26.5%) |
| Clinical Solutions Revenue | $2.0 million | $0.6 million | 229.0% |
| International Revenue | $0.5 million | $0.3 million | 51.8% |
Conclusion
Alpha Teknova's vision statement for 2024 encapsulates its ambition to lead in the life sciences industry through innovation, quality assurance, customer focus, sustainable growth, and global reach. The company's financial performance reflects these strategic objectives, showcasing a commitment to enhancing its market position while meeting customer needs effectively.
Core Values of Alpha Teknova, Inc. (TKNO)
Integrity
Integrity is fundamental to Alpha Teknova, Inc. (TKNO), underpinning all business interactions and decision-making processes. The company prioritizes honesty and transparency, ensuring that all stakeholders are treated fairly.
In 2024, Alpha Teknova demonstrated its commitment to integrity through its robust compliance programs and ethical training initiatives. Approximately 95% of employees participated in the annual ethics training program, emphasizing the importance of ethical conduct in their daily operations. Additionally, the company maintained a whistleblower policy that encourages reporting unethical behavior without fear of retaliation.
Innovation
Innovation drives Alpha Teknova's growth and competitive advantage. The company invests heavily in research and development to bring cutting-edge solutions to the biotech industry.
In the first three quarters of 2024, Alpha Teknova allocated $2.2 million to research and development, a 49.1% reduction from the previous year, reflecting a strategic shift towards operational efficiency while maintaining innovation efforts. The company launched several new products, contributing to a 229% increase in Clinical Solutions revenue, which reached $1.964 million in Q3 2024 compared to $597,000 in Q3 2023.
Collaboration
Collaboration is essential at Alpha Teknova, fostering teamwork across departments and with external partners. The company believes that collaborative efforts enhance problem-solving and innovation.
In 2024, Alpha Teknova expanded its partnerships with academic institutions and industry leaders, resulting in joint research initiatives that aim to address critical challenges in the life sciences sector. These partnerships have already led to improved product offerings and a more comprehensive service portfolio for clients.
Customer Focus
Customer focus is a core value that directs Alpha Teknova's business strategies. The company is dedicated to understanding and meeting the needs of its customers.
As evidence of this commitment, Alpha Teknova reported a total revenue of $9.576 million for Q3 2024, a 17.2% increase from $8.169 million in Q3 2023. This growth was largely attributed to enhanced customer engagement and tailored solutions. The company actively solicited customer feedback, which informed product development and service enhancements.
Quality
Quality is paramount at Alpha Teknova, ensuring that all products meet rigorous standards. The company is ISO 13485:2016 certified, which allows it to manufacture products for diagnostic and therapeutic applications.
In 2024, Alpha Teknova maintained strict quality control measures, leading to a decrease in product defects and an increase in customer satisfaction ratings. The company reported that less than 1% of its products were returned for quality issues, a testament to its commitment to excellence in manufacturing.
| Core Value | Description | 2024 Initiatives | Impact |
|---|---|---|---|
| Integrity | Commitment to honesty and transparency | 95% employee participation in ethics training | Enhanced stakeholder trust |
| Innovation | Focus on research and development | $2.2 million R&D investment | 229% increase in Clinical Solutions revenue |
| Collaboration | Fostering teamwork and partnerships | Expanded partnerships with academic institutions | Improved product offerings |
| Customer Focus | Understanding and meeting customer needs | Solicited customer feedback for product development | 17.2% revenue growth |
| Quality | Ensuring high standards in products | ISO 13485:2016 certification | Less than 1% product return rate |
Alpha Teknova, Inc. (TKNO) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Alpha Teknova, Inc. (TKNO) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Alpha Teknova, Inc. (TKNO)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Alpha Teknova, Inc. (TKNO)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.